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Platelets are central to thrombus formation, the leading cause of global mortality.1 Antiplatelet drugs are of proven ben-
efit for the treatment and prevention of atherothrombotic events 
in many clinical settings, but despite the introduction of newer 
agents in the last decade, important limitations persist. Aspirin 
and P2Y12 antagonists, the current standard of care oral anti-
platelet agents in patients with acute coronary syndrome, 
stroke, and peripheral arterial disease, prevent thromboxane 
A2 and ADP platelet activation, respectively.2–7 However, nei-
ther is effective against thrombin, the most potent of all platelet 
agonists,8 and both are associated with an increased incidence 
of bleeding that restricts their use in sensitive populations 
(eg, elderly, cerebrovascular disease) and reduces their net 
clinical benefit.5,9–12 Thus, despite contemporary antiplatelet 
pharmacotherapy, many patients remain at high risk of future 
atherothrombotic events,5–7,10,13,14 and there is a clear need for 
newer agents that can provide equivalent (or superior) anti-
thrombotic efficacy with an improved safety profile.
See accompanying editorial on page 287
In recent years, PAR4 (protease-activated receptor 4) antago-
nism has emerged as promising new antiplatelet strategy. PAR4 
is a G-protein coupled receptor expressed on the platelet sur-
face that together with PAR1 (protease-activated receptor 1) is 
responsible for thrombin-mediated platelet activation and aggre-
gation.15 Thrombin has a key role in the coagulation cascade, but 
by targeting the platelet receptor rather than the protease, this 
avoids directly interfering with thrombin-induced fibrin pro-
duction. PAR1 has greater affinity for thrombin than PAR4, but 
© 2017 The Authors. Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and 
reproduction in any medium, provided that the original work is properly cited.
Objective—BMS-986120 is a novel first-in-class oral PAR4 (protease-activated receptor 4) antagonist with potent and selective 
antiplatelet effects. We sought to determine for the first time, the effect of BMS-986120 on human ex vivo thrombus formation.
Approach and Results—Forty healthy volunteers completed a phase 1 parallel-group PROBE trial (Prospective Randomized 
Open-Label Blinded End Point). Ex vivo platelet activation, platelet aggregation, and thrombus formation were measured 
at 0, 2, and 24 hours after (1) oral BMS-986120 (60 mg) or (2) oral aspirin (600 mg) followed at 18 hours with oral 
aspirin (600 mg) and oral clopidogrel (600 mg). BMS-986120 demonstrated highly selective and reversible inhibition of 
PAR4 agonist peptide (100 μM)-stimulated P-selectin expression, platelet-monocyte aggregates, and platelet aggregation 
(P<0.001 for all). Compared with pretreatment, total thrombus area (μm2/mm) at high shear was reduced by 29.2% (95% 
confidence interval, 18.3%–38.7%; P<0.001) at 2 hours and by 21.4% (9.3%–32.0%; P=0.002) at 24 hours. Reductions 
in thrombus formation were driven by a decrease in platelet-rich thrombus deposition: 34.8% (19.3%–47.3%; P<0.001) at 
2 hours and 23.3% (5.1%–38.0%; P=0.016) at 24 hours. In contrast to aspirin alone, or in combination with clopidogrel, 
BMS-986120 had no effect on thrombus formation at low shear (P=nonsignificant). BMS-986120 administration was not 
associated with an increase in coagulation times or serious adverse events.
Conclusions—BMS-986120 is a highly selective and reversible oral PAR4 antagonist that substantially reduces platelet-rich 
thrombus formation under conditions of high shear stress. Our results suggest PAR4 antagonism has major potential as a 
therapeutic antiplatelet strategy.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02439190.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38: 
448-456. DOI: 10.1161/ATVBAHA.117.310104.)
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despite early clinical promise, the addition of vorapaxar (the only 
licensed PAR1 antagonist) to standard care failed to meet its pri-
mary efficacy outcome in patients with acute coronary syndrome 
and was associated with an excess of major bleeding, especially 
intracranial hemorrhage, in phase3 clinical trials.13,16 PAR4 was 
originally thought to simply provide some redundancy to PAR1 
platelet signaling at high thrombin concentrations.17 However, 
due to differences in activation kinetics and downstream path-
ways, it is now evident that PAR1 and PAR4 have distinct and 
complementary roles in the early and late phases of platelet 
activation and aggregation, respectively.18–20 PAR1 activation 
is brisk but transient and requires input from the P2Y12-PI3K 
(phosphatidylinositol 3-kinase) pathway to maintain platelet 
aggregation.19,20 In contrast, PAR4 is activated at higher throm-
bin concentrations and induces a slow but prolonged intracellular 
signal that acts independently to sustain irreversible aggrega-
tion.17,18,20 Furthermore, PAR4 activation occurs after ADP secre-
tion, and thrombin depends on PAR4 but not PAR1 to induce 
full platelet spreading.21 Thus, several lines of evidence indicate 
that while PAR1 and other agonist-signaling pathways may have 
important roles in initiating platelet activation, the primary func-
tion of PAR4 appears to be in sustaining irreversible platelet 
aggregation and thrombus propagation. This suggests that selec-
tively targeting PAR4-mediated thrombin activity may protect 
against occlusive thrombus formation while avoiding interfering 
with hemostatic platelet responses to the same extent as PAR1 
antagonists and other antiplatelet agents.22
BMS-986120 is a first-in-class, oral, highly selective, and 
reversible PAR4 antagonist antiplatelet agent. In preclinical ani-
mal models, BMS-986120 demonstrated potent antithrombotic 
activity with a substantially wider therapeutic window when 
compared with clopidogrel.22 The purpose of the present phase 
1 parallel-group PROBE trial (Prospective Randomized Open-
Label Blinded End Point) was to build on these observations and 
examine for the first time, the antiplatelet and antithrombotic 
effects of BMS-986120 in humans using a translational model 
of ex vivo thrombosis. We determined whether reductions in 
thrombus formation were driven by a decrease in platelet-rich or 
fibrin-rich thrombus formation and whether these effects were 
greater under rheological conditions of low or high shear stress.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
All 40 volunteers (81 volunteers were screened) completed the 
study in full. The demographics and baseline characteristics of 
study volunteers were similar in the 2 treatment groups (Table). 
BMS-986120 was well tolerated with no clinically significant 
effect on any of the biochemical, hematologic, coagulation, 
physical, or ECG safety assessments conducted throughout 
the study (Table I in the online-only Data Supplement). There 
were no serious adverse events. One episode of minor bleed-
ing was reported. This occurred 12 hours after aspirin admin-
istration, self-resolved, and did not recur.
Pharmacokinetic Profile of Oral BMS-986120
BMS-986120 was rapidly absorbed with peak plasma con-
centrations occurring at 2 hours (255±136 ng/mL; Figure 1). 
Plasma concentrations of BMS-986120 were halved by 4 
hours (133±100 ng/mL) and <10% of the peak concentration 
by 24 hours (21±9 ng/mL).
Effect of BMS-986120 on Platelet 
Activation and Aggregation
BMS-986120 demonstrated strong and reversible inhibition 
of PAR4 agonist peptide (AP; 100 μM)-stimulated plate-
let activation and aggregation (P<0.001 for all). Compared 
with pretreatment, PAR4 AP-stimulated increases in plate-
let P-selectin expression (%), platelet-monocyte aggre-
gates (%), and platelet aggregation (%) were reduced by 
91.7% (95% confidence interval [CI], 81.0–102.4), 80.6% 
(95% CI, 68.6%–92.6%), and 85.0% (95% CI, 82.0–88.1) 
at 2 hours and by 53.9% (95% CI, 43.2%–64.7%), 41.1% 
(95% CI, 28.9%–53.2%), and 6.0% (95% CI, 2.9%–9.0%) 
at 24 hours (P<0.001 for all; Figure 2). Plasma concentra-
tions of BMS-986120 correlated with P-selectin expression 
(ρ=−0.87), platelet-monocyte aggregates (ρ=−0.88), and 
platelet aggregation (ρ=−0.82; P<0.001 for all; Figure III 
in the online-only Data Supplement). There was no effect 
on PAR1 AP, ADP, or arachidonic acid platelet responses 
(P=nonsignificant [ns] for all; Figure 2).
Effect of Aspirin±Clopidogrel 
on Platelet Aggregation
Aspirin administration reduced arachidonic acid-stimulated 
platelet aggregation by 74.5% (95% CI, 71.6%–77.3%; 
P<0.001). In combination with clopidogrel, aspirin reduced 
arachidonic acid-stimulated platelet aggregation by 73.7% 
(95% CI, 70.9%–76.5%; P<0.001) and ADP-stimulated 
platelet aggregation by 41.9% (95% CI, 35.2%–48.7%; 
P<0.001), respectively (Figure IV in the online-only Data 
Supplement).
Effect of BMS-986120 on Ex Vivo 
Thrombus Formation
BMS-986120 reduced total thrombus formation at high shear 
(P<0.001) but not at low shear (P=ns; Figure 3). Compared 
with pretreatment, total thrombus area (μm2/mm) at high shear 
was reduced by 29.2% (95% CI, 18.3%–38.7%; P<0.001) at 
2 hours and by 21.4% (95% CI, 9.3%–32.0%; P=0.002) at 24 
hours. Plasma concentrations of BMS-986120 correlated with 
total thrombus formation at high shear (ρ=−0.47; P<0.001) 
but not at low shear (ρ=−0.18; P=ns; Figure III in the online-
only Data Supplement).
Nonstandard Abbreviations and Acronyms
AP agonist peptide
CI confidence interval
ns nonsignificant
PAR protease-activated receptor
PI3K phosphatidylinositol 3-kinase
PROBE prospective randomized open-label blinded end point
TF tissue factor
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Reductions in total thrombus area were driven by a 
decrease in platelet deposition (Figure 4). At high shear, 
platelet-rich thrombus area was reduced by 34.8% (95% CI, 
19.3%–47.3%; P<0.001) at 2 hours and 23.3% (95% CI, 
5.1%–38.0%; P=0.016) at 24 hours. Reductions in fibrin-
rich thrombus area at 2 (−14.7%; 95% CI, −22.5% to −6.2%; 
P=0.002) and 24 hours (−7.9%; 95% CI, −16.3% to 1.4%; 
P=0.09) were small by comparison. BMS-986120 had no 
effect on either platelet-rich or fibrin-rich thrombus formation 
at low shear (P=ns for all).
Effect of Aspirin±Clopidogrel on Ex 
Vivo Thrombus Formation
Aspirin and aspirin in combination with clopidogrel both 
reduced thrombus formation at high and low shear, also 
driven by decrease in platelet-rich thrombus. Aspirin 
reduced total thrombus area and platelet-rich thrombus area 
by 30.2% (95% CI, 15.6%–42.2%; P<0.001) and 41.7% 
(95% CI, 22.9%–56.0%; P<0.001), respectively, and by 
32.4% (95% CI, 18.3%–44.0%; P<0.001) and 46.4% (95% 
CI, 29.1%–59.5%; P<0.001), respectively, when used in 
combination with clopidogrel.
In contrast to BMS-986120, aspirin and aspirin in combi-
nation with clopidogrel both reduced total thrombus area at 
low shear (−17.4%; 95% CI, −27.0% to −6.5%; P=0.003 and 
−13.5%; 95% CI, −23.6% to −2.1%; P=0.02). There was no 
effect on fibrin-rich thrombus deposition at low or high shear 
(P=ns for all).
Discussion
In this phase 1 PROBE designed clinical trial, we have 
shown for the first time that PAR4 antagonism with 
BMS-986120 reduces ex vivo human thrombus formation 
under conditions representative of deep arterial injury in 
a stenosed coronary artery. BMS-986120 demonstrated 
selective and reversible antiplatelet effects with concen-
tration-dependent inhibition of thrombus formation and 
PAR4 AP-stimulated platelet activation and aggregation. 
Our results provide further insights into the role of PAR4 in 
human thrombogenesis and raise major promise for BMS-
986120 as an antiplatelet agent in the treatment and preven-
tion of arterial thrombosis.
Assessment of the antiplatelet and antithrombotic effects 
of PAR4 inhibition has previously been limited by a lack of 
compound specificity and availability.23–25 In comparison with 
earlier compounds, including P4pal-10, YD-3, and its deriva-
tive ML354,25–27 BMS-986120 has antiplatelet activity against 
α thrombin, demonstrated greater potency and selectivity of 
effect in preclinical and phase 1 studies of platelet inhibition, 
and is the first orally bioavailable PAR4 antagonist.22,28 In the 
present study, a single dose of BMS-986120 resulted in near 
complete inhibition of PAR4 AP-stimulated platelet activa-
tion and aggregation at 2 hours, with a return toward base-
line at 24 hours. Importantly, there was no effect on PAR1 
AP, ADP, or arachidonic acid-stimulated platelet activity. Our 
data, therefore, add to previous studies indicating that BMS-
986120 is a highly selective and reversible antiplatelet agent 
with potent activity against PAR4-stimulated platelet activa-
tion and aggregation in humans.
The antithrombotic effects of BMS-986120 in humans 
were examined using the Badimon perfusion chamber—a 
well validated model for measuring ex vivo thrombus forma-
tion in humans.29–36 Using the same model and under the same 
flow conditions, previous studies in healthy volunteers have 
demonstrated reductions in high shear thrombus formation of 
18.7% after a single 300-mg oral dose of clopidogrel, 28% 
with a 60-mg oral dose of edoxaban and 56% with extracor-
poreal coadministration of tirofiban (50 ng/mL).29,36,37 In the 
present study, a single dose of BMS-986120 (60 mg) reduced 
high shear thrombus formation by nearly a third. This is con-
sistent with preclinical animal data22,23 and comparable with 
reductions in thrombus formation we observed with high load-
ing doses of aspirin and clopidogrel. Importantly, therefore, 
we have shown that oral PAR4 antagonism with BMS-986120 
substantially reduces ex vivo human thrombus formation. 
Moreover, reductions were similar in magnitude to clinically 
approved antiplatelet agents suggesting a high probability of 
in vivo antithrombotic efficacy.
Table. Baseline Characteristics of Study Volunteers
Test Variable
BMS-986120 
(n=20)
Aspirin±Clopidogrel 
(n=20)
Men (%) 20 (100) 20 (100)
Age, y (SD) 23.6 (3.4) 28.7 (10.0)
BMI, kg/m2 (SD) 23.6 (2.6) 25.4 (3.5)
Race (%)
  White 19 (95) 19 (95)
  Black/African 1 (5) 0
  Asian 0 1 (5)
Hemoglobin, g/dL (SD) 14.2 (0.42) 14.6 (0.85)
Platelet count, ×109 c/L (SD) 230 (45) 221 (49)
APTT, s (SD) 30.9 (2.2) 30.8 (2.6)
PT, s (SD) 12.3 (0.9) 11.9 (0.7)
APTT indicates activated partial thromboplastin time; BMI, body mass index; 
and PT, prothrombin time.
Figure 1. Pharmacokinetics of BMS-986120. BMS-986120 was 
rapidly absorbed with a half-life of 4 h. Data shown are mean 
plasma concentrations of BMS-986120 (±95% confidence inter-
vals) after administration of a single oral 60-mg dose.
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Figure 2. BMS-986120 demonstrated highly selective, potent, and reversible inhibition of PAR (protease-activated receptor) 4-stimulated 
platelet activation and aggregation. Box plots of platelet activation and aggregation in response to (A–C) PAR4 Agonist peptide (AP; 100 
μM), (D and E) PAR1 AP (100 μM), (F) PAR1 AP (25 μM), (G) ADP (10 μM), and (H) arachidonic acid (AA; 5 mmol/L), in volunteers (Continued )
D
ow
nloaded from
 http://ahajournals.org by on January 15, 2019
452  Arterioscler Thromb Vasc Biol  February 2018
BMS-986120 seemed to have less of an effect on throm-
bus formation at low shear than either aspirin alone or aspirin 
in combination with clopidogrel. Although further studies are 
required to confirm whether PAR4 antagonism is more selec-
tive for inhibiting thrombus formation at high shear than exist-
ing agents, distinct mechanisms of platelet aggregation are 
known to operate under different rheological conditions.38,39 
Low shear rates reflect flow conditions found in patent epi-
cardial arteries and some veins, whereas the majority of ath-
erothrombotic events invariably occur at areas of high shear 
stress seen in diseased arteries.40,41 Indeed, most myocardial 
infarctions arise from stenotic atherosclerotic plaques with 
rheological conditions comparable with those in our high 
shear chamber.42–44 Antiplatelet agents that are more selective 
for inhibiting thrombus formation at high shear may allow at-
risk vascular beds to be targeted with greater specificity. Given 
many treatment-related bleeding events are likely to occur 
from vessels with low shear rates,45–49 this could facilitate a 
wider safety profile.
As expected from an antiplatelet agent, reductions in 
thrombus were driven by a decrease in platelet deposition; 
however, there was also a small but significant reduction in 
fibrin-rich thrombus formation. PAR4 is reported to be the 
predominant platelet PAR responsible for phosphatidylser-
ine exposure, microparticle shedding, and thrombin genera-
tion.50 Our results add to these studies, indicating that PAR4 
may have a role in platelet procoagulant activity during ex 
vivo human thrombus formation. Whether this is beneficial or 
not is uncertain, but it is worth noting BMS-986120 was not 
associated with an increase in coagulation assay times, and 
no bleeding-related clinical findings or adverse events were 
reported in a previous phase 1 single- and multiple-ascending 
dose study.28
PAR4 is expressed within the vasculature, and PAR4 
antagonism may, in addition to protecting against throm-
bosis, serve to limit vascular complications in at-risk 
patients. Human vascular smooth muscle cells upregulate 
PAR4 in response to glucose,51 and elevated expression of 
A
B C
Figure 3. BMS-986120 reduced thrombus formation at high shear but not at low shear. A, Representative image of porcine aortic media 
exposed to human blood at high shear stained to quantify total thrombus area. Sections were stained with polyclonal goat antihuman 
fibrin(ogen) antibody and CD61 monoclonal mouse antihuman antibody before treatment with 3,3′-diaminobenzidine substrate chromo-
gen. Sections were then counterstained with a modified Masson trichrome (hematoxylin and sirius red, 0.1%). Effect of (B) BMS-986120 
and (C) aspirin (ASA)±clopidogrel (Clop.) on total thrombus area at high and low shear. Statistical comparisons (least significance differ-
ence test) vs 0 h are represented above each plot. ns indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
Figure 2 Continued. randomized to BMS-986120. Data shown are the adjusted mean (+) normalized to unstimulated values. The line 
within the box represents the median, upper and lower edges of the box represent the 75th and 25th percentiles, and upper and lower 
whiskers represent the 95th and 5th percentiles. Statistical comparisons (least significance difference test) vs 0 h are represented above 
each plot. ns indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
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PAR4 has been reported in the tunica media of atherec-
tomy and saphenous vein tissue from patients with diabetes 
mellitus.51 Moreover, PAR4 deficiency protected against 
excessive remodeling induced by carotid artery ligation in 
streptozotocin-diabetic mice.52 PAR4, therefore, seems to 
be a key regulator of exaggerated intimal thickening in diabe-
tes mellitus, and future studies examining the antiproliferative 
potential of PAR4 antagonism would be of significant thera-
peutic interest.
Our study has some limitations. First, although the 
exposed porcine aortic media presents many of the common 
constituents of a disrupted atherosclerotic plaque, includ-
ing type I collagen, it may not contain tissue factor (TF).53–55 
TF activates the coagulation cascade and is an important 
Figure 4. Reductions in thrombus formation were driven by a decrease in platelet-rich thrombus formation. Representative image of 
thrombus formed at high shear stained to allow quantification of (A) platelet-rich and (B) fibrin-rich thrombus area. Sections were stained 
with polyclonal goat antihuman fibrin(ogen) antibody and CD61 monoclonal mouse antihuman antibody before counterstaining with tyra-
mide Cy3 (cyanine 3) and FITC (fluorescein isothiocyanate). Effect of (C) BMS-986120 and (D) aspirin (ASA)±clopidogrel (Clop.) on platelet 
and fibrin deposition at low and high shear. Data shown are adjusted means±95% confidence intervals. Statistical comparisons (least sig-
nificance difference test) vs 0 h are represented above each plot. ns indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
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contributor to thrombogenicity.56,57 Nevertheless, this does 
not overly limit our model for the assessment of thrombosis 
because binding of blood-borne circulating TF is sufficient 
to allow activation of the coagulation cascade and thrombus 
propagation.53,54,58–60 Indeed, previous studies have demon-
strated that thrombus formed from human blood perfused 
over exposed porcine tunica media (devoid of TF) stains 
heavily for TF.53,54 Second, we assessed a single oral dose 
of BMS-986120 and did not explore the effect of prolonged 
BMS-986120 administration on thrombus formation, such 
as would occur with the secondary prevention of myocardial 
infarction and stroke. However, because this was the phase 1 
trial designed to examine the antithrombotic effects of oral 
PAR4 antagonism in humans for the first time, we felt our 
study design was appropriate. Third, BMS-986120 was dosed 
in isolation, and future studies to determine the antiplatelet 
and antithrombotic effects of PAR4 antagonism in combina-
tion with current agents would be of interest. Finally, although 
no episodes of bleeding occurred in volunteers administered 
BMS-986120 and BMS-986120 was not associated with an 
increase in bleeding times in a previous phase 1 safety and 
tolerability study,28 the safety profile of PAR4 antagonism in 
humans remains to be defined.
In conclusion, we have demonstrated that PAR4 antago-
nism with BMS-986120—a highly selective and reversible 
oral PAR4 antagonist—substantially reduces ex vivo throm-
bus formation in healthy volunteers under conditions of high 
shear stress. BMS-986120 was well tolerated with no change 
in coagulation assays or serious adverse events. Given the 
potential hemostatic sparing effects of PAR4 antagonism, 
our results suggest that BMS-986120 has major potential as a 
novel antiplatelet agent and that further investigation in clini-
cal trials is warranted.
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Highlights
• Inhibition of thrombin-mediated platelet activation through PAR4 (protease-activated receptor 4) antagonism represents a promising new 
antiplatelet strategy because of the potential for reduced bleeding.
• BMS-986120 is a first-in-class, oral, highly selective, and reversible PAR4 antagonist antiplatelet agent.
• A single dose of BMS-986120 substantially reduced ex vivo thrombus formation in healthy volunteers under conditions of high shear stress, 
driven by a reduction in platelet-rich thrombus deposition.
• Our results suggest PAR4 antagonism with BMS-986120 holds major promise as a novel antiplatelet strategy because of the potential for a 
wider therapeutic window in terms of antithrombotic efficacy and bleeding risk.
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